Human papillomavirus infection among head and neck squamous cell carcinomas in southern China


Autoři: Guoying Ni aff001;  Kunsong Huang aff001;  Yi Luan aff003;  Zaizai Cao aff004;  Shu Chen aff003;  Bowei Ma aff001;  Jianwei Yuan aff001;  Xiaolian Wu aff003;  Guoqiang Chen aff003;  Tianfang Wang aff002;  Hejie Li aff002;  Shelley Walton aff005;  Fang Liu aff003;  Bobei Chen aff004;  Yuejian Wang aff003;  Xuan Pan aff001;  Xiaosong Liu aff001;  Ian H. Frazer aff006
Působiště autorů: The First Affiliated Hospital/Clinical Medical School, Guangdong Pharmaceutical University, Guangzhou, Guangdong, China aff001;  Genecology Research Centre, University of the Sunshine Coast, Maroochydore DC, QLD, Australia aff002;  Cancer Research Institute, Foshan First People’s Hospital, Foshan, Guangdong, China aff003;  The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China aff004;  Inflammation and Healing Research Cluster, School of Health and Sport Sciences, University of Sunshine Coast, Maroochydore DC, QLD, Australia aff005;  The University of Queensland, Faculty of Medicine, Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia aff006
Vyšlo v časopise: PLoS ONE 14(9)
Kategorie: Research Article
doi: 10.1371/journal.pone.0221045

Souhrn

Human papillomavirus (HPV) related tumours account for a significant proportion of head and neck squamous cell carcinomas (HNSCCs) in developed countries. They respond better to chemo- and radio-therapy, and have a better stage specific prognosis. To establish their prevalence in China, we assessed a series of histology confirmed HNSCCs collected in Zhejiang and Guangdong provinces by PCR for HPV DNA and by immunohistochemistry for p16 protein status. Among 303 HNSCCs, HPV DNA was detected in 26.4%, with HPV16 DNA in 71% of these. Of HNSCC located in the oropharynx, 38.55% (32/83) were HPV+ve. In this series, p16 status was a relatively poor predictor of HPV status as detected by PCR. The stage specific survival time of HPV+ HNSCCs was significantly longer than for HPV- HNSCC. HPV status should be assessed for oropharyngeal cancers in China to assist with appropriate management, and prophylaxis against HPV infection should be considered to reduce the incidence of this disease.

Klíčová slova:

Cancer treatment – Cell staining – Head and neck squamous cell carcinoma – Human papillomavirus – Human papillomavirus infection – China – Polymerase chain reaction – HPV-16


Zdroje

1. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016;91(3):386–96. doi: 10.1016/j.mayocp.2015.12.017 26944243.

2. Kounis NG. Kounis syndrome: an update on epidemiology, pathogenesis, diagnosis and therapeutic management. Clin Chem Lab Med. 2016;54(10):1545–59. doi: 10.1515/cclm-2016-0010 26966931.

3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. 15761078.

4. Li S, Lee YC, Li Q, Chen CJ, Hsu WL, Lou PJ, et al. Oral lesions, chronic diseases and the risk of head and neck cancer. Oral Oncol. 2015;51(12):1082–7. doi: 10.1016/j.oraloncology.2015.10.014 26526128.

5. Liu J, Yang XL, Zhang SW, Zhu LP, Chen WQ. Incidence, mortality, and temporal patterns of oropharyngeal cancer in China: a population-based study. Cancer Commun (Lond). 2018;38(1):75. doi: 10.1186/s40880-018-0345-5 30594248.

6. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781–9. doi: 10.1016/S1470-2045(10)70017-6 20451455; PubMed Central PMCID: PMC5242182.

7. Wiegand S, Wichmann G, Golusinski W, Leemans CR, Klussmann JP, Dietz A. Highlights from the Second International Symposium on HPV infection in head and neck cancer. Eur Arch Otorhinolaryngol. 2018;275(6):1365–73. doi: 10.1007/s00405-018-4954-z 29589141.

8. Syrjanen S. Oral manifestations of human papillomavirus infections. Eur J Oral Sci. 2018;126 Suppl 1:49–66. doi: 10.1111/eos.12538 30178562.

9. Lee LA, Huang CG, Tsao KC, Liao CT, Kang CJ, Chang KP, et al. Human Papillomavirus Infections are Common and Predict Mortality in a Retrospective Cohort Study of Taiwanese Patients With Oral Cavity Cancer. Medicine (Baltimore). 2015;94(47):e2069. doi: 10.1097/MD.0000000000002069 26632712; PubMed Central PMCID: PMC5058981.

10. Lam EW, Chan JY, Chan AB, Ng CS, Lo ST, Lam VS, et al. Prevalence, Clinicopathological Characteristics, and Outcome of Human Papillomavirus-Associated Oropharyngeal Cancer in Southern Chinese Patients. Cancer Epidemiol Biomarkers Prev. 2016;25(1):165–73. doi: 10.1158/1055-9965.EPI-15-0869 26604268.

11. Chor JS, Vlantis AC, Chow TL, Fung SC, Ng FY, Lau CH, et al. The role of human papillomavirus in head and neck squamous cell carcinoma: A case control study on a southern Chinese population. J Med Virol. 2016;88(5):877–87. doi: 10.1002/jmv.24405 26467027.

12. Rabelo-Goncalves E, Roesler B, Guardia AC, Milan A, Hara N, Escanhoela C, et al. Evaluation of five DNA extraction methods for detection of H. pylori in formalin-fixed paraffin-embedded (FFPE) liver tissue from patients with hepatocellular carcinoma. Pathol Res Pract. 2014;210(3):142–6. doi: 10.1016/j.prp.2013.11.003 24355442.

13. Janecka A, Adamczyk A, Gasinska A. Comparison of eight commercially available kits for DNA extraction from formalin-fixed paraffin-embedded tissues. Anal Biochem. 2015;476:8–10. doi: 10.1016/j.ab.2015.01.019 25640584.

14. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357–61. 10618116; PubMed Central PMCID: PMC88724.

15. Sun P, Song Y, Ruan G, Mao X, Kang Y, Dong B, et al. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study. J Gynecol Oncol. 2017;28(5):e50. doi: 10.3802/jgo.2017.28.e50 28657218; PubMed Central PMCID: PMC5540716.

16. Zhang Y, Wang Y, Liu L, Guo C, Liu Z, Nie S. Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China. Oncotarget. 2016;7(38):62411–24. doi: 10.18632/oncotarget.11498 27566561; PubMed Central PMCID: PMC5308736.

17. Pesek M, Kinkorova I, Ferko R, Urgeova A, Bouda J. [Evaluation of p16 protein in the managementof cervical dysplasia]. Ceska Gynekol. 2013;78(2):195–9. 23710985.

18. Pinatti LM, Walline HM, Carey TE. Human Papillomavirus Genome Integration and Head and Neck Cancer. J Dent Res. 2018;97(6):691–700. doi: 10.1177/0022034517744213 29227715; PubMed Central PMCID: PMC5960877.

19. Gotz C, Bischof C, Wolff KD, Kolk A. Detection of HPV infection in head and neck cancers: Promise and pitfalls in the last ten years: A meta-analysis. Mol Clin Oncol. 2019;10(1):17–28. doi: 10.3892/mco.2018.1749 30655973; PubMed Central PMCID: PMC6313947.

20. Termine N, Panzarella V, Falaschini S, Russo A, Matranga D, Lo Muzio L, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988–2007). Ann Oncol. 2008;19(10):1681–90. doi: 10.1093/annonc/mdn372 18558666.

21. Guo L, Yang F, Yin Y, Liu S, Li P, Zhang X, et al. Prevalence of Human Papillomavirus Type-16 in Head and Neck Cancer Among the Chinese Population: A Meta-Analysis. Front Oncol. 2018;8:619. doi: 10.3389/fonc.2018.00619 30619756; PubMed Central PMCID: PMC6299118.

22. Ceccarelli M, Rullo EV, Facciola A, Madeddu G, Cacopardo B, Taibi R, et al. Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review. Oncotarget. 2018;9(24):17171–80. doi: 10.18632/oncotarget.24660 29682214; PubMed Central PMCID: PMC5908315.

23. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol. 2015;33(29):3235–42. doi: 10.1200/JCO.2015.61.6995 26351338; PubMed Central PMCID: PMC4979086.

24. Kobayashi K, Hisamatsu K, Suzui N, Hara A, Tomita H, Miyazaki T. A Review of HPV-Related Head and Neck Cancer. J Clin Med. 2018;7(9). doi: 10.3390/jcm7090241 30150513.

25. Vokes EE, Agrawal N, Seiwert TY. HPV-Associated Head and Neck Cancer. J Natl Cancer Inst. 2015;107(12):djv344. doi: 10.1093/jnci/djv344 26656751.

26. Tong F, Geng J, Yan B, Lou H, Chen X, Duan C, et al. Prevalence and Prognostic Significance of HPV in Laryngeal Squamous Cell Carcinoma in Northeast China. Cell Physiol Biochem. 2018;49(1):206–16. doi: 10.1159/000492858 30134232.

27. Wei W, Shi Q, Guo F, Zhang BY, Chen C, Zhang NS, et al. The distribution of human papillomavirus in tissues from patients with head and neck squamous cell carcinoma. Oncol Rep. 2012;28(5):1750–6. doi: 10.3892/or.2012.1990 22923266.

28. Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269–82. doi: 10.1038/nrc.2018.11 29497144.

29. LeConte BA, Szaniszlo P, Fennewald SM, Lou DI, Qiu S, Chen NW, et al. Differences in the viral genome between HPV-positive cervical and oropharyngeal cancer. PloS one. 2018;13(8):e0203403. doi: 10.1371/journal.pone.0203403 30161236; PubMed Central PMCID: PMC6117069.

30. Richards L. Human papillomavirus-a powerful predictor of survival in patients with oropharyngeal cancer. Nat Rev Clin Oncol. 2010;7(9):481. doi: 10.1038/nrclinonc.2010.123 20824898.

31. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35. doi: 10.1056/NEJMoa0912217 20530316; PubMed Central PMCID: PMC2943767.

32. Smola S, Trimble C, Stern PL. Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. Ther Adv Vaccines. 2017;5(3):69–82. doi: 10.1177/2051013617717914 28794879; PubMed Central PMCID: PMC5524244.

33. van der Sluis TC, van der Burg SH, Arens R, Melief CJ. New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer. Curr Opin Immunol. 2015;35:9–14. doi: 10.1016/j.coi.2015.05.002 26001120.

34. Ni G, Wang T, Walton S, Zhu B, Chen S, Wu X, et al. Manipulating IL-10 signalling blockade for better immunotherapy. Cell Immunol. 2015;293(2):126–9. doi: 10.1016/j.cellimm.2014.12.012 25596475.


Článek vyšel v časopise

PLOS One


2019 Číslo 9

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se